| Literature DB >> 31113748 |
Yi-Heng Li1, Jaw-Wen Chen2, Tsung-Hsien Lin3, Yu-Chen Wang4, Chau-Chung Wu5, Hung-I Yeh6, Chin-Chou Huang7, Kuan-Cheng Chang8, Cho-Kai Wu9, Po-Wei Chen1, Chen-Wei Huang1, Zhih-Cherng Chen10, Wei-Ting Chang11, Wei-Chun Huang12, Chih-Yuan Wang13, Mei-Yueh Lee14, A-Ching Chao15, Wei-Ren Fu16, Li-Kai Tsai17, Sung-Chun Tang17, Hsin-Lung Chan18, Yi-Ching Yang19, Yen-Wen Wu20, Juey-Jen Hwang21, Jiunn-Lee Lin22.
Abstract
Atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease, cerebrovascular disease, and peripheral artery disease, carries a high morbidity and mortality. Risk factor control is especially important for patients with ASCVD to reduce recurrent cardiovascular events. Clinical guidelines have been developed by the Taiwan Society of Cardiology, Taiwan Society of Lipids and Atherosclerosis, and Diabetes Association of Republic of China (Taiwan) to assist health care professionals in Taiwan about the control of hypertension, hypercholesterolemia and diabetes mellitus. This article is to highlight the recommendations about blood pressure, cholesterol, and sugar control for ASCVD. Some medications that are beneficial for ASCVD were also reviewed. We hope the clinical outcomes of ASCVD can be improved in Taiwan through the implementation of these recommendations.Entities:
Keywords: Atherosclerosis; Performance guide; Risk factors
Year: 2019 PMID: 31113748 DOI: 10.1016/j.jfma.2019.04.007
Source DB: PubMed Journal: J Formos Med Assoc ISSN: 0929-6646 Impact factor: 3.282